- Home
- PANW vs SNY Comparison
PANW vs SNY Comparison
Compare PANW & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PANW
- SNY
- Stock Information
- Founded
- PANW 2005
- SNY 1994
- Country
- PANW United States
- SNY France
- Employees
- PANW N/A
- SNY N/A
- Industry
- PANW Computer peripheral equipment
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- PANW Technology
- SNY Health Care
- Exchange
- PANW Nasdaq
- SNY Nasdaq
- Market Cap
- PANW 124.9B
- SNY 116.5B
- IPO Year
- PANW 2012
- SNY N/A
- Fundamental
- Price
- PANW $204.27
- SNY $48.12
- Analyst Decision
- PANW Buy
- SNY Buy
- Analyst Count
- PANW 45
- SNY 2
- Target Price
- PANW $208.31
- SNY $62.50
- AVG Volume (30 Days)
- PANW 4.1M
- SNY 2.1M
- Earning Date
- PANW 08-18-2025
- SNY 07-24-2025
- Dividend Yield
- PANW N/A
- SNY 3.31%
- EPS Growth
- PANW N/A
- SNY 39.56
- EPS
- PANW 1.74
- SNY 5.45
- Revenue
- PANW $8,874,700,000.00
- SNY $48,817,552,946.00
- Revenue This Year
- PANW $16.74
- SNY $3.39
- Revenue Next Year
- PANW $14.13
- SNY $7.05
- P/E Ratio
- PANW $117.40
- SNY $8.86
- Revenue Growth
- PANW 13.90
- SNY N/A
- 52 Week Low
- PANW $142.01
- SNY $45.80
- 52 Week High
- PANW $208.39
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- PANW 59.92
- SNY 41.60
- Support Level
- PANW $196.00
- SNY $47.56
- Resistance Level
- PANW $202.89
- SNY $48.93
- Average True Range (ATR)
- PANW 4.05
- SNY 0.64
- MACD
- PANW 0.17
- SNY -0.06
- Stochastic Oscillator
- PANW 66.51
- SNY 26.24
About PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.